Everything below concerns trans-3-hexenoyl. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
== Epidemiology == Acanthosis nigricans is reported worldwide, with prevalence varying by age, ethnicity and underlying metabolic risk. In clinic- and community-based samples of people with obesity and insulin resistance, reported prevalence ranges from about 7% to over 70%, depending on the population and diagnostic criteria used. Higher rates are consistently observed among individuals of African, Hispanic/Latino, Native American and some Asian ancestries, reflecting both genetic susceptibility and a higher burden of obesity and metabolic syndrome in many of these populations. In children and adolescents, the prevalence of acanthosis nigricans has risen alongside increasing rates of overweight and obesity and is common in pediatric cohorts with insulin resistance or metabolic syndrome. Across studies, acanthosis nigricans is more frequent among people with higher body mass index, increased waist circumference and biochemical markers of insulin resistance.
=== Contestants === 1st - Michelle Antonishek, Executive Pastry Chef from Cotulla, Texas 2nd - Tamara Brown, Home Baker from Baldwin Park, California 3rd - Veronica von Borstel, Cake Designer from San Diego, California 4th - John Schopp, Pastry Instructor from Roanoke, Virginia 5th - Amy Strickland, Bakery Owner from Lake City, Florida1 6th - Damien Bagley, Pastry Instructor from Las Vegas, Nevada 7th - Brad Rudd, Bakery Manager from Encino, California ^Note 1: Amy Strickland withdrew from the competition, just before the start of the third episode, due to stress concerns since she was 6 months pregnant.
== Early life == Elizabeth Evans Hughes was born August 19, 1907, in the New York State Executive Mansion in Albany, New York, to Antoinette (Carter) and Charles Evans Hughes, who was Governor of New York at the time. Elizabeth developed diabetes in 1918 at age 11. At the time, the life expectancy of a Type 1 diabetic without treatment was usually no more than a few months. Since it was unable to metabolize sugars, the diabetic body would instead begin to burn fats. The dependence on fat would eventually lead to acidosis, followed by coma and death. The only known treatment was a low-carbohydrate low-calorie diet at a level that the patient could tolerate without showing sugar in the urine. If the diet was carefully observed, diabetics could expect to live for a couple of years before eventually succumbing to starvation, organ damage, or an infectious disease in their malnourished state. In spring 1919, Elizabeth Hughes was brought to Dr. Frederick Madison Allen at his special clinic, the Physiatric Institute in Morristown, New Jersey. Allen put her on a strict diet and continued to monitor her condition over the next three years while she lived at home with a private nurse. She was 4 feet 11.5 inches (1.511 m) and 75 pounds (34 kg) when she developed diabetes. Under diets that averaged 800 calories per day, her weight fell to 45 pounds (20 kg) by August 1922.
Sources: en.wikipedia.org
=== Plan-generate-test paradigm === The plan-generate-test paradigm is the basic organization of the problem-solving method, and is a common paradigm used by both Heuristic Dendral and Meta-Dendral systems. The generator (later named CONGEN) generates potential solutions for a particular problem, which are then expressed as chemical graphs in Dendral. However, this is feasible only when the number of candidate solutions is minimal. When there are large numbers of possible solutions, Dendral has to find a way to put constraints that rules out large sets of candidate solutions. This is the primary aim of Dendral planner, which is a “hypothesis-formation” program that employs “task-specific knowledge to find constraints for the generator”. Last but not least, the tester analyzes each proposed candidate solution and discards those that fail to fulfill certain criteria. This mechanism of plan-generate-test paradigm is what holds Dendral together.
=== Subsidiaries === 2GO Express, Inc. – Provides land, air, and sea transportation including courier services, general cargo, sea cargo services, and last-mile delivery for e-commerce. It operates a nationwide network of retail outlets and partner agents and partners with FedEx for international express services. 2GO Logistics, Inc. – Provides transportation, warehousing, cross-docking, trucking, domestic freight, and inventory management solutions nationwide. Kerry Logistics (Phils.), Inc. (KLPI) – A joint venture with Kerry Logistics Network Limited of Hong Kong, offering domestic and international freight forwarding, warehousing, distribution, customs brokerage, project logistics, and handling of dangerous goods. 2GO Land Transport, Inc. – Provides cargo hauling and forwarding via trucks, container vans, and closed vans. 2GO Retail – Offers domestic parcel delivery, FedEx international services, and 2GO Travel ticket sales through retail outlets and partner agents. Special Container and Value Added Services, Inc. (SCVASI) – Provides cold chain and liquid bulk transport solutions, including temperature-controlled vans and ISO tanks for FCL and LCL shipments, as well as project logistics for industries such as infrastructure, power, telecommunications, mining, and property. 2GO operates passenger and freight services connecting major ports across the Philippines, linking Luzon, the Visayas, and Mindanao.
== Consumer acceptance == Historically, consumers paid little attention to food technologies. Nowadays, the food production chain is long and complicated and food technologies are diverse. Consequently, consumers are uncertain about the determinants of food quality and find it difficult to understand them. Now, acceptance of food products very often depends on perceived benefits and risks associated with food. Popular views of food processing technologies matter. Especially innovative food processing technologies often are perceived as risky by consumers. Acceptance of the different food technologies varies. While pasteurization is well recognized and accepted, high pressure treatment and even microwaves often are perceived as risky. Studies by the Hightech Europe project found that traditional technologies were well accepted in contrast to innovative technologies. Consumers form their attitude towards innovative food technologies through three main mechanisms: First, through knowledge or beliefs about risks and benefits correlated with the technology; second, through attitudes based on their own experience; and third, through application of higher order values and beliefs. A number of scholars consider the risk-benefit trade-off as one of the main determinants of consumer acceptance, although some researchers place more emphasis on the role of benefit perception (rather than risk) in consumer acceptance.
Sources: en.wikipedia.org
== Approval == The patch was granted a license from the European Medicines Agency in July, and is available on Britain's National Health Service from March 2007. However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use. In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months.
== External links == CUTL1+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human CUX1 genome location and CUX1 gene details page in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
By 1945 she had succeeded in identifying the structure of vitamin B12, describing the arrangement of its atoms in three dimensions. In 1947, she was elected a Fellow of the Royal Society (FRS) In 1958, she was elected a Foreign Honorary Member of the American Academy of Arts and Sciences. Hodgkin won the 1964 Nobel Prize in Chemistry, and is the only British woman scientist to have been awarded a Nobel Prize in any of the three sciences it recognizes. In 1965 she was appointed to the Order of Merit. She was the second woman to receive the Order. In 1966, she was awarded the Iota Sigma Pi National Honorary Member for her significant contribution. In 1970, gained EMBO Membership. She became a foreign member of the USSR Academy of Sciences in the 1970s. In 1976, she was the first woman to receive the prestigious Copley Medal. Hodgkin was Chancellor of the University of Bristol from 1970 to 1988. In 1978, she was given an honorary Degree of Science from University of Bath. In 1981, she was awarded the Dalton Medal from the Manchester Literary and Philosophical Society In 1982 she received the Lomonosov Medal of the Soviet Academy of Sciences. In 1987 she accepted the Lenin Peace Prize from the government of Mikhail Gorbachev. In 1983, Hodgkin received the Austrian Decoration for Science and Art. In 1993, an asteroid (5422) discovered on 23 December 1982 by L.G. Karachkina (at the Crimean Astrophysical Observatory, M.P.C. 22509, in the USSR) was named "Hodgkin" in her honour.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。